Quoin Pharmaceuticals, Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
QNRX Nasdaq 2830 quoinpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy - Oct 20th, 2026 4:30 am
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome - Oct 14th, 2026 4:30 am
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy - Oct 6th, 2026 4:30 am
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome - Sep 22nd, 2026 6:30 am
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU - Sep 10th, 2026 6:30 am
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome - Sep 8th, 2026 12:12 pm
Quoin in line for priority review voucher if rare paediatric drug approved - Sep 8th, 2026 11:28 am
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome - Sep 8th, 2026 6:30 am
Sector Update: Healthcare Stocks Decline Friday Afternoon - Aug 28th, 2026 11:34 am
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million - Aug 28th, 2026 4:00 am
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome - Aug 28th, 2026 4:00 am
QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization - Aug 27th, 2026 9:25 am
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Aug 14th, 2026 6:30 am
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 - Aug 7th, 2026 6:30 am
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome - Jul 9th, 2026 6:30 am
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome - Jun 30th, 2026 6:30 am
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - Jun 23rd, 2026 6:30 am
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 - Jun 18th, 2026 6:30 am
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program - Jun 16th, 2026 6:30 am
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome - Jun 4th, 2026 6:30 am